Overview of Dr. Yamshon
Dr. Samuel Yamshon is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital and New York-Presbyterian Hospital. He received his medical degree from University of California, Davis, School of Medicine and has been in practice 0 years. He is one of 368 doctors at New York-Presbyterian Hospital and one of 368 doctors at New York-Presbyterian Hospital who specialize in Oncology. He has more than 10 publications and over 100 citings.
Office
520 East 70th Street
Starr Pavilion, 3rd Floor
New York, NY 10021- Is this information wrong?
Education & Training
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2016 - 2019
University of California, Davis, School of MedicineClass of 2016
Certifications & Licensure
NY State Medical License 2019 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Safety and Toxicity Profiles of CAR T Cell Therapy in Non-Hodgkin Lymphoma: A Systematic Review and Meta-Analysis.Caitlin Gribbin, Zhengming Chen, Michelle Demetres, Michelle Pasciolla, Samuel Yamshon, Mohammad Alhomoud, Nora Chokr, John Leonard, Tsiporah Shore, Peter Martin> ;Clinical Lymphoma, Myeloma & Leukemia. 2024 Feb 15
- 2 citationsNine-year follow-up of lenalidomide plus rituximab as initial treatment for mantle cell lymphoma.Samuel Yamshon, Gui Zhen Chen, Caitlin Gribbin, Paul Christos, Bijal Shah, Stephen J Schuster, Sonali M Smith, Jakub Svoboda, Richard R Furman, John P Leonard, Peter M...> ;Blood Advances. 2023 Nov 14
- Deposition of complement components C5b-9 and MASP2 in tissues is not a feature of GVHD and may assist in discriminating GVHD from thrombotic microangiopathy following...Mohammad Alhomoud, Cynthia Magro, Surya Seshan, Taotao Zhang, Alexandra Gomez-Arteaga, Nora Chokr, Samuel Yamshon, Adrienne Phillips, Sebastian Mayer, Tsiporah Shore, ...> ;Bone Marrow Transplantation. 2023 Nov 1
- Join now to see all
Abstracts/Posters
- Markers of Lenalidomide and Rituximab Treatment in Indolent Non-Hodgkins LymphomaYamshon S, Qi L, et al., UC Davis Research Symposium, UC Davis, 4/2014
- Correlative Analysis and Clinical Update Of a Phase II Study Using Lenalidomide and Rituximab In Patients With Indolent Non-Hodgkin Lymphoma.Yamshon S, Qi L, Yu C, et al., Blood, 12/2013
Lectures
- Non-Destructive Post-Transplant Lymphoproliferative Disorder Shows Distinct Clinical Features with HHV-6 Reactivation in a Subset61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Bioethics and Transgender HealthUniversity of Pennsylvania - 10/2014
- Ethical Decision-MakingHarvard University - 10/2014
- Join now to see all
Press Mentions
- The Battle for Frontline Therapy on MCL: Lenalidomide plus RituximabMarch 2nd, 2021
Mantle Cell Lymphoma: Long-Extending Remissions with Lenalidomide, RituximabDecember 16th, 2020
Professional Memberships
- Member
Hospital Affiliations
New York-Presbyterian HospitalNew York, New York- New York-Presbyterian HospitalNew York, New York
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
